unknown
Stage
1
Investors
About
Eledon Pharmaceuticals develops tegoprubart, an anti-CD40L antibody designed to prevent organ transplant rejection by modulating the immune response, and is conducting global clinical trials focused on kidney and other organ transplants.
Explore Eledon's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.